Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. (NASDAQ: CDXS) generates news primarily around its enzymatic technologies for therapeutics manufacturing and the development of its ECO Synthesis® / ECO Synthesis™ manufacturing platform. The company’s announcements frequently highlight progress in applying enzyme-based processes to small molecule pharmaceuticals manufacturing and nucleic acid synthesis, as well as steps toward enabling scaled manufacture of RNAi therapeutics, including siRNA and other oligonucleotides, through enzymatic routes.
News about Codexis often covers financial results and business updates, where the company reports on revenues, product gross margins, research and development spending, and strategic priorities. These releases typically include commentary on the performance of its Pharma Biocatalysis business, the status of ECO Synthesis-related activities, and the company’s cash position and funding plans as disclosed in its quarterly and annual reporting cycles.
Another recurring theme in Codexis news is collaborations and evaluation agreements with organizations involved in oligonucleotide therapeutics. The company has announced agreements with CDMOs and CRDMOs such as Nitto Denko Avecia and Axolabs to evaluate the ECO Synthesis manufacturing platform for therapeutic siRNA and other oligonucleotides. These updates describe how partners assess Codexis’s enzymatic approach and indicate that such evaluations may lead to licensing discussions and broader adoption.
Codexis also issues news about infrastructure and strategic initiatives, including the signing of a lease for a GMP manufacturing facility in Hayward, California, intended to support GMP manufacturing of siRNA and other oligonucleotides using ECO Synthesis. Additional releases detail organizational changes, leadership transitions, workforce streamlining aligned with an enhanced focus on ECO Synthesis, and participation in industry conferences such as TIDES USA and TIDES Europe, where Codexis and its collaborators present data on enzymatic manufacturing technologies.
Investors and observers who follow CDXS news can use this stream of updates to monitor Codexis’s progress in advancing enzyme-based manufacturing platforms, its relationships with manufacturing partners, and its evolving strategic focus within therapeutics manufacturing.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Codexis (NASDAQ: CDXS) announced it will release its financial results for Q1 2023 on May 4, 2023, after market closure. The company will not hold a conference call following this release. Codexis specializes in enzyme engineering, utilizing its CodeEvolver® technology platform to develop high-performance enzymes for various applications, including pharmaceuticals and biotherapeutics. Their technology aims to enhance manufacturing efficiency, reduce energy consumption, and improve therapeutic efficacy. The company's innovations address challenges in small molecule production, nucleic acid synthesis, and genomic sequencing.
Codexis (NASDAQ: CDXS) will host a workshop at the TIDES USA annual meeting on May 7, 2023, focusing on enzymatic solutions for RNA-based therapeutics manufacturing. As RNA therapeutics, particularly mRNA vaccines and siRNA candidates, gain momentum, challenges in production quality, quantity, and economics persist. Codexis aims to showcase how its engineered enzymes can address these issues, potentially enhancing scalability and sustainability in the manufacturing process.
The presentation, titled 'Engineered Enzymes to Overcome Scalability and Sustainability Challenges of Nucleic Acid Therapeutics Manufacturing,' will take place from 12:30 PM to 1:30 PM PT at Manchester Grand Hyatt in San Diego, CA. An archive will be available to registered attendees on the TIDES USA platform and Codexis' website.
Codexis, Inc. (NASDAQ: CDXS), an enzyme engineering leader, has announced the approval of equity grants for two new employees. The grants include options to purchase 14,881 shares of common stock and restricted stock units (RSUs) for 8,928 shares. These awards serve as inducement under the company’s 2022 Employee Inducement Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to the closing price on the grant date and will vest over four years, while RSUs will vest annually over three years. Codexis specializes in high-performance enzymes with applications in pharmaceuticals, genetic research, and therapeutics, contributing to manufacturing efficiency and improved health solutions.
On April 4, 2023, Codexis announced that Patrick Yang, PhD, will not seek re-election to its Board of Directors after serving since 2014. Yang, who chaired the Nominating and Corporate Governance Committee, was recognized for his significant contributions to the company. The Board expressed gratitude for his leadership during his tenure. Codexis noted that Yang's departure comes after strengthening the Board with new members experienced in biomanufacturing and gene therapy. Dr. Yang expressed confidence in Codexis's future under its current leadership, highlighting the company's transformation in Life Sciences and Biotherapeutics.
Codexis (NASDAQ: CDXS), an enzyme engineering company, announced the approval of equity grants for two new hires as sanctioned by its Compensation Committee. The awards include stock options for 43,403 shares and restricted stock units (RSUs) for 9,723 shares, as part of the 2022 Employee Inducement Incentive Award Plan. Stock options will have an exercise price based on the closing price on the grant date and vest over four years. RSUs will vest annually over three years. This move aims to attract and retain talent in the competitive biotech sector.
Codexis, a leader in enzyme engineering, will participate in the Cowen 43rd Annual Health Care Conference from March 6-8, 2023, in Boston, Massachusetts. Stephen Dilly, CEO, will join a panel discussion on 'SynBio & AI Driven Drug Discovery' on March 6 at 4:40 pm ET. The management team will also engage in a fireside chat on March 7 at 11:10 am ET. Interested investors can access webcasts of both events on the company's Investor Relations webpage, with the panel archived for 30 days and the chat for 90 days. Codexis utilizes its CodeEvolver® platform to develop innovative enzymes and biotherapeutics for various applications, enhancing manufacturing and therapeutic efficacy.